Navigation Links
Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
Date:3/9/2009

SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its fourth quarter and year ended December 31, 2008 financial results on Thursday, March 12, 2009 after the markets close. The announcement will be followed by a live webcast and conference call at 2:00 p.m. Pacific time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 860-2442 (domestic) or (412) 858-4600 (international). The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
2. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
3. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
4. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
9. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
10. Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009
11. ExonHit Therapeutics Shareholders Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation ... of the American Association of Bioanalysts (AAB) and the College of Reproductive Biology ... conference reinforces AAB’s commitment to excellence in clinical laboratory services and regulations. ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. ... 2017 at the Prince Of Wales Private Hospital. The procedure was performed on ... The patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... its scientific power by providing investigators access to a high-profile scientific advisory ... the scientific advisory board. “We are committed to offering superior services and ...
(Date:5/18/2017)... (PRWEB) , ... May 17, 2017 , ... ... construction, announced today that their Chief Executive Officer, Maik Jornitz, was recognized as ... UK publication’s Power List celebrates 100 individuals “involved in bettering the pharma industry ...
Breaking Biology Technology:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):